Shares of BENITEC BIOPHAR/S (NASDAQ:BNTC) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $4.65 and traded as low as $3.20. BENITEC BIOPHAR/S shares last traded at $3.20, with a volume of 9,000 shares.
Separately, ValuEngine upgraded BENITEC BIOPHAR/S from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd.
The company has a current ratio of 20.29, a quick ratio of 7.10 and a debt-to-equity ratio of 0.02. The stock has a fifty day moving average of $4.63 and a 200 day moving average of $3.38.
About BENITEC BIOPHAR/S (NASDAQ:BNTC)
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B.
Featured Article: How liquidity affects the bid-ask spread
Receive News & Ratings for BENITEC BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BENITEC BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.